Contribution of endogenous glucagon-like peptide 1 to prandial counterregulatory responses to hypoglycemia after bariatric surgery

Henri Honka; Amalia Gastaldelli; Samantha Pezzica; Richard Peterson; Ralph DeFronzo; Marzieh Salehi

doi:10.1101/2023.09.20.23295840

ABSTRACT

Aims/hypothesis Exogenous glucagon-like peptide 1 (GLP-1) infusion lowers endogenous glucose production (EGP) in euglycemic or hyperglycemic settings. Previously, we have shown that prandial EGP during insulin-induced hypoglycemia is smaller in non-diabetic subjects with gastric bypass (GB) and sleeve gastrectomy (SG), where prandial GLP-1 concentrations are increased by 5-10 fold compared to non-operated controls. The goal of this study was to determine the effect of endogenous GLP-1 on prandial counterregulatory response to hypoglycemia.

Methods Glucose fluxes and islet-cell and gut hormone responses before and after mixed-meal ingestion were compared among 8 subjects with prior GB, 7 with prior SG, and 5 matched non-surgical controls during a hyperinsulinemic (120 mU/min/m²) hypoglycemic (∼3.2 mmol/l) clamp with and without a specific GLP-1 receptor (GLP-1R) antagonist exendin-(9-39) (Ex-9).

Results Before meal ingestion, plasma glucagon and glucose fluxes were similar among 3 groups. GLP-1R blockade had no effect on insulin secretion or insulin action before or after meal ingestion whereas prandial glucagon was enhanced in all 3 groups (P < 0.05). Ex-9 infusion raised prandial EGP response to hypoglycemia in surgical groups (P < 0.05) but decreased this parameter in controls (P = 0.08 for interaction). The rates of systemic appearance of ingested glucose or prandial glucose utilization did not differ among 3 groups and between studies with and without Ex-9 infusion.

Conclusions/interpretation Under hypoglycemic condition, the glucagonostatic effect, but not insulinotropic action of GLP-1, is preserved in the prandial condition in humans. Endogenous GLP-1 contributes to the impaired post-meal glucose counterregulatory response to hypoglycemia in non-diabetic subjects after bariatric surgery.

RESEARCH IN CONTEXT What is already known about this subject?

The physiologic response to hypoglycemia includes the inhibition of insulin secretion, followed by stimulation of counterregulatory hormones, mainly glucagon, raising endogenous glucose production (EGP).
Glucagon-like peptide 1 (GLP-1) has been shown to diminish EGP by direct or indirect effect on liver glucose metabolism.
Rerouted gut after gastric bypass or sleeve gastrectomy, where prandial GLP-1 secretion is enhanced, leads to a blunted EGP response to insulin-induced hypoglycemia in the fed state.

What is the key question?

To determine the contribution of endogenous GLP-1 to post-meal counterregulatory response to hypoglycemia in individuals with and without prior bariatric surgery.

What are the new findings?

Under hypoglycemic conditions, the glucagonostatic effect, but not insulinotropic action of GLP-1 is preserved, indicating differential glucose-dependency of this peptide on pancreatic alpha- versus beta-cells.
Endogenous GLP-1 contributes to diminished prandial EGP response to hypoglycemia in non-diabetic subjects after bariatric surgery.

How might this impact on clinical practice in the foreseeable future?
The results of this study support the use of GLP-1 receptor antagonists as therapeutic targets in post-bariatric hypoglycemia and related conditions.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT02823665

Funding Statement

This study was funded by National Institute of Diabetes and Digestive and Kidney Diseases (DK105379) and by Finnish Cultural Foundation (no. 00180071).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of the University of Texas Health Science Center at San Antonio gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

All data generated or analyzed during this study are included in this published article (and its supplementary information files). Authors have nothing to disclose conflicting with the content of the current manuscript. The reported investigations have been carried out in accordance with principles of the Declaration of Helsinki as revised in 2008. This study is registered on ClinicalTrials.gov (NCT02823665).